Labetalol (versus unexposed) updated on 12-17-2024

Caesarean

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14403
R57203		 Xiang, 2020 Cesarean delivery during pregnancy (anytime or not specified) randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: Only chronic hypertension indication 0.92 [0.54;1.57] C 38/127   40/126 78 127
ref
S13912
R54427		 Duan, 2018 Cesarean during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 3.09 [2.88;3.31] C 1,825/3,357   104,203/374,391 106,028 3,357
ref
S14267
R56083		 Cruickshank, 1991 Emergency caesarean sections 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified 0.57 [0.20;1.63] C 6/51   12/63 18 51
ref
Total 3 studies 1.27 [0.43;3.76] 106,124 3,535
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Xiang, 2020Xiang, 2020 0.92[0.54; 1.57]7812735%ROB confusion: lowROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Duan, 2018Duan, 2018 3.09[2.88; 3.31]106,0283,35738%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Cruickshank, 1991Cruickshank, 1991 0.57[0.20; 1.63]185128%ROB confusion: lowROB selection: unclearROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 93% 1.27[0.43; 3.76]106,1243,5350.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 3.09[2.88; 3.31]106,0283,357 -NADuan, 2018 1 case control studiescase control studies 0 RCTRCT 0.83[0.52; 1.34]961780%NAXiang, 2020 Cruickshank, 1991 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 3.09[2.88; 3.31]106,0283,357 -NADuan, 2018 1 unexposed, sickunexposed, sick 0.83[0.52; 1.34]961780%NAXiang, 2020 Cruickshank, 1991 2 Tags Adjustment   - No  - No 3.09[2.88; 3.31]106,0283,357 -NADuan, 2018 1   - Randomisation  - Randomisation 0.83[0.52; 1.34]961780%NAXiang, 2020 Cruickshank, 1991 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.44[0.28; 7.53]106,0463,40890%NADuan, 2018 Cruickshank, 1991 2   - Only chronic hypertension indication  - Only chronic hypertension indication 0.92[0.54; 1.57]78127 -NAXiang, 2020 1 All studiesAll studies 1.27[0.43; 3.76]106,1243,53593%NAXiang, 2020 Duan, 2018 Cruickshank, 1991 30.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 3.09[2.88; 3.31]106,0283,357 -NADuan, 2018 1 unexposed, sick controlsunexposed, sick controls 0.83[0.52; 1.34]961780%NAXiang, 2020 Cruickshank, 1991 20.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION (Caesarean section) 1.02[0.77; 1.33]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT4 Firoz (Caesarean section (Labetalol iv versus ...Firoz (Caesarean section (Labetalol iv versus Nifedipine)) 0.81[0.51; 1.32]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Firoz (Caesarean section (Labetalol versus Me ...Firoz (Caesarean section (Labetalol versus Methyldopa)) 0.85[0.56; 1.30]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Bellos (Cesarean delivery (Randomized control ...Bellos (Cesarean delivery (Randomized controlled trial and Cohort studies)) 0.96[0.59; 1.57]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bellos (Cesarean delivery (Randomized control ...Bellos (Cesarean delivery (Randomized controlled trial only)) 0.96[0.59; 1.57]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 1.27[0.43; 3.76]93%3,535----Xiang, 2020 Duan, 2018 Cruickshank, 1991 30.510.01.0